AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30202072
Drug: Inferonasal (IN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inferonasal (IN) injection
Trial: 30202072
Drug: Superotemporal (ST)
RxNorm normalized name: ST-36
DrugBank: ST-36 (DB17275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superotemporal (ST) injection
Trial: 30202072
Drug: Inferotemporal (IT)
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inferotemporal (IT) injection
Trial: 26505342
Drug: High-dose interferon-α-2b
RxNorm normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interferon-α-2b (IFN-α-2b)
Trial: 26505342
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no high-dose IFN-α-2b)
Trial: 23868265
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment (Control)
Trial: 20924615
Drug: NSAID (diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID (diclofenac sodium, 75 mg/day) and omeprazole (20 mg/day) with placebo
Trial: 20924615
Drug: Rebamipide co-therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide co-therapy
Trial: 15377321
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg phenazone
Trial: 10511067
Drug: Buprenorphine 4
RxNorm normalized name: buprenorphine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 4 mg/70 kg
Trial: 10511067
Drug: Buprenorphine 8
RxNorm normalized name: buprenorphine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 8 mg/70 kg
Trial: 10511067
Drug: Higher dosing
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dosing regimens (48, 72, 96 hours)
Trial: 7489530
Drug: nifedipine-GITS 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine-GITS 30 mg
Trial: 7489530
Drug: nifedipine-GITS 60
RxNorm normalized name: nifedipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine-GITS 60 mg
Trial: 1722967
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose iloprost (0.5 ng/kg/min)
Trial: 1722967
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose iloprost (2 ng/kg/min)
Trial: 31865326
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (1 strength, 10,000 TU/mL)
Trial: 31865326
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (standard, 7 injections with 1,000 TU/mL and 10,000 TU/mL)
Trial: 30762267
Drug: Cuminum cyminum
RxNorm normalized name: CUMINUM CYMINUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuminum cyminum L. (CuEO) essential oil, 75 mg, thrice daily for 8 weeks
Trial: 30762267
Drug: Cuminum cyminum
RxNorm normalized name: CUMINUM CYMINUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuminum cyminum L. (CuEO) essential oil
Trial: 30762267
Drug: Placebo soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo soft gel
Trial: 27128727
Drug: Psychoeducational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational therapy in addition to routine follow-up
Trial: 17882136
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg iron and 1 mg riboflavin weekly for 6 months
Trial: 17882136
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg zinc and 1 mg riboflavin weekly for 6 months
Trial: 17882136
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg iron, 20 mg zinc and 1 mg riboflavin weekly for 6 months
Trial: 17882136
Drug: Riboflavin alone
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin alone (control) weekly for 6 months
Trial: 17245230
Drug: 3-drug efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-drug efavirenz (ZDV/3TC + EFV)
Trial: 17245230
Drug: 4-drug efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-drug efavirenz (ZDV/3TC/ABC + EFV)
Trial: 11923756
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 microg subcutaneous)
Trial: 11923756
Drug: Hydrocortisone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (100 mg intravenous)
Trial: 9872337
Drug: Clindamycin phosphate/tretinoin
RxNorm normalized name: CLINDAMYCIN PHOSPHATE/TRETINOIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate/tretinoin gel
Trial: 9872337
Drug: Clindamycin HCl/tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin HCl/tretinoin gel
Trial: 9872337
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate lotion (1% clindamycin; Dalacin T)
Trial: 9872337
Drug: Clindamycin phosphate/tretinoin
RxNorm normalized name: CLINDAMYCIN PHOSPHATE/TRETINOIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate/tretinoin gel in acne patients
Trial: 7613151
Drug: Allergen injection
RxNorm normalized name: catfish allergenic extract
DrugBank: Diphenylpyraline (DB01146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allergen injection immunotherapy
Trial: 31008759
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of autologous platelet-rich plasma and fibrin glue (PRP-FG) into the wound after wide excision of the sinus with primary closure
Trial: 20627942
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion of antithrombin concentrate (100 IU/min) before full-dose heparinisation
Trial: 20627942
Drug: Fast infusion
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast infusion of antithrombin concentrate (250 IU/min)
Trial: 20627942
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (slow and fast infusion)
Trial: 17091331
Drug: High-dose adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adjuvant chemotherapy (mitomycin and tegafur-uracil)
Trial: 17091331
Drug: Low-dose adjuvant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose adjuvant chemotherapy (mitomycin and tegafur-uracil)
Trial: 15602113
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg paroxetine
Trial: 12080675
Drug: Xixian tongshuan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xixian tongshuan pill (XTP)
Trial: 8614309
Drug: Palmvitee (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmvitee (40 mg alpha-tocopherol, 48 mg alpha-tocotrienol, 112 mg gamma-tocotrienol, and 60 mg delta-tocotrienol/day for four weeks)
Trial: 8614309
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg gamma-tocotrienol/day for four weeks
Trial: 8614309
Drug: Tocotrienol preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocotrienol preparations
Trial: 8614309
Drug: Neither preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither preparation
Trial: 2076798
Drug: Subcutaneous glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous glucagon (1 mg)
Trial: 2076798
Drug: Glycocholic acid
RxNorm normalized name: Glycocholic acid
DrugBank: Glycocholic acid (DB02691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycocholic acid (1 mg)
Trial: 7039058
Drug: Gentamicin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (1 mg/kg/iv q8h)
Trial: 7039058
Drug: Tobramycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (1 mg/kg/iv q8h)
Trial: 30328105
Drug: Paroxetine (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (selective serotonin reuptake inhibitor)
Trial: 28655183
Drug: Internet-delivered therapist-guided
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered therapist-guided cognitive behavior therapy for insomnia
Trial: 28655183
Drug: Internet-delivered therapist-guided
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered therapist-guided cognitive behavior therapy for depression
Trial: 24332687
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia with cocaine 4% pledgets
Trial: 24332687
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia with lidocaine 2% plus 1/100.000 adrenaline pledgets
Trial: 22849337
Drug: Carvedilol 6.25‐12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 6.25‐12.5 mg daily
Trial: 22849337
Drug: Nadolol 40‐80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 40‐80 mg plus isosorbide‐5‐mononitrate 20 mg daily
Trial: 19726349
Drug: Parenteral plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral plus enteral nutrition (PN+EN)
Trial: 16301340
Drug: Thalidomide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (25 mg QD increasing to 200 mg QD)
Trial: 9456273
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 120 mg sustained-release once daily
Trial: 9456273
Drug: Molsidomine 8
RxNorm normalized name: molsidomine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine 8 mg sustained-release 3 times daily
Trial: 2146996
Drug: Infusions of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions of third-party donor leucocytes
Trial: 30014671
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of parecoxib sodium (40 mg), combined with regular anesthesia
Trial: 30014671
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of dezocine (5 mg), combined with regular anesthesia
Trial: 17623736
Drug: IVIG 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 0.4 g/kg per month
Trial: 16220024
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (prior to antidepressive treatment)
Trial: 9923795
Drug: Exogenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exogenous insulin (n = 8)
Trial: 2103755
Drug: Micronutrient antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient antioxidant therapy (daily doses of 600 micrograms organic selenium, 9000 IU beta carotene, 0.54 g vitamin C, 270 IU vitamin E, and 2 g methionine)
Trial: 29490041
Drug: Solution-focused wellness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-focused wellness intervention (seven-week duration)
Trial: 24582799
Drug: Calcium lactate
RxNorm normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium lactate pre-rinse (CaL, 150mmol/L, 1min) followed by fluoride rinse (NaF 12mmol/L, 1min)
Trial: 24582799
Drug: Fluoride rinse
RxNorm normalized name: ACT Fluoride Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride rinse only (NaF 12mmol/L, 1min)
Trial: 22257577
Drug: NVA237 (glycopyrronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 (glycopyrronium bromide) at doses of 25, 50, 100, or 200 μg
Trial: 8707580
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream corresponding to Optiderm
Trial: 6197081
Drug: Radiotherapy to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy to the primary site followed by 10 pulses of chemotherapy (cyclophosphamide, methotrexate, CCNU)
Trial: 6197081
Drug: Two pulses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two pulses of chemotherapy (cyclophosphamide, methotrexate, CCNU) followed by radiotherapy and then 8 pulses of chemotherapy
Trial: 22810146
Drug: CMV serostatus
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV serostatus (measured by CMV IgG antibodies)
Trial: 20216555
Drug: Active FM
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active FM (fermented milk containing Lactobacillus gasseri SBT2055), n=43, 200 g/day for 12 weeks
Trial: 20216555
Drug: Control FM
RxNorm normalized name: FM-VP4
DrugBank: FM-VP4 (DB05449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control FM (fermented milk without Lactobacillus gasseri SBT2055), n=44, 200 g/day for 12 weeks
Trial: 17505679
Drug: Active TEA
RxNorm normalized name: IODINE 100 g in 100 g TOPICAL CREAM [Active Teat Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active TEA (15 ml 0.5% bupivacaine)
Trial: 17505679
Drug: Placebo (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (15 ml 0.9% saline)
Trial: 8533119
Drug: Phenytoin 100
RxNorm normalized name: phenytoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin 100 mg/day, 200 mg/day, or 300 mg/day for 14 weeks
Trial: 31283908
Drug: nabilone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nabilone (0.5 mg)
Trial: 31283908
Drug: nicotine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nicotine (6 mg)
Trial: 31283908
Drug: nicotine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nicotine (6 mg) + nabilone (0.5 mg)
Trial: 23004922
Drug: Low-dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose ASA (100 mg/d) ingested 8 hours after awakening
Trial: 23004922
Drug: Low-dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose ASA (100 mg/d) ingested at bedtime
Trial: 23004922
Drug: Low-dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose ASA (100 mg/d) ingested upon awakening
Trial: 23004922
Drug: Low-dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose ASA (100 mg/d)
Trial: 10929272
Drug: Corticosteroids or
RxNorm normalized name: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids or adrenocorticotropic hormone (ACTH) treatment
Trial: 10929272
Drug: Corticosteroids or
RxNorm normalized name: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids or ACTH treatment
Trial: 1344236
Drug: Intramuscular meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular meperidine 25mg IM
Trial: 6424464
Drug: Oral nonabsorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nonabsorbable antibiotics and isolation in laminar airflow room (36 patients)
Trial: 6424464
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment in single rooms with hand-washing and mask precautions (31 patients)
Trial: 15547093
Drug: Infliximab treatment
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab treatment (5 mg/kg)
Trial: 9747153
Drug: rt-PA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA (20 mg administered locoregionally over 4 hours for a maximum of 7 days)
Trial: 9747153
Drug: urokinase (100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urokinase (100,000 IU/h administered locoregionally for a maximum of 7 days)
Trial: 9747153
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (intravenous heparin infusions after PTT)
Trial: 2467608
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ST) - penicillin-chloramphenicol combination with or without sulphadiazine
Trial: 31586206
Drug: 13-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13) during maintenance chemotherapy (Group 1)
Trial: 31586206
Drug: 13-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13) at end of chemotherapy (Group 2)
Trial: 31586206
Drug: 13-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13) 6 months after chemotherapy (Group 3)
Trial: 28292331
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for depression, 16-20 sessions
Trial: 26430087
Drug: Increased urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased urinary excretion of urea nitrogen (≥ 8 g/d)
Trial: 16862612
Drug: TEP laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEP laparoscopic patch repair
Trial: 10165553
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement patch (Prostep, Lederle Laboratories) with no additional support (Group I, n = 166)
Trial: 10165553
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement patch (Prostep, Lederle Laboratories) with 24-hour telephone hotline support (Group II, n = 167)
Trial: 10165553
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement patch (Prostep, Lederle Laboratories) with 24-hour telephone hotline support and four follow-up calls (Group III, n = 167)
Trial: 8475816
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg fusidic acid (intervention)
Trial: 3823635
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose of prednisolone
Trial: 30661105
Drug: CBD alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD alone (400 mg)
Trial: 30661105
Drug: THC alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC alone (8 mg)
Trial: 30661105
Drug: THC combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC combined with low dose CBD (4 mg)
Trial: 30661105
Drug: THC combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC combined with high dose CBD (400 mg)
Trial: 29110150
Drug: 30-min, vigorous-intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-min, vigorous-intensity treadmill bout 24 hours prior to each of four doxorubicin treatments
Trial: 19226891
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and conventional rehabilitation therapy
Trial: 19226891
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation therapy (Control)
Trial: 10232685
Drug: Continued ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued ramipril (1.25 to 5 mg/d)
Trial: 6287359
Drug: Physostigmine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (single IV infusion)
Trial: 23639793
Drug: Antipsychotic trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic trials with adequate allocation concealment, double blinding, higher precision, larger trial size, at least three treatment arms, recent publication, conducted in the United States, and enrollment of inpatients
Trial: 21317283
Drug: Tolvaptan 15
RxNorm normalized name: tolvaptan 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 15 mg daily (titrated to 30 and 60 mg if necessary)
Trial: 16934685
Drug: Oltipraz 125
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz 125 mg daily